Trials / Unknown
UnknownNCT04518982
Sintilimab and Lenalidomide as a Treatment for CAEBV
Sintilimab and Lenalidomide as a Treatment for CAEBV：a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Zhao Wang · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, prospective, randomized, controlled clinical study to evaluate the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with chronic active EBV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab and lenalidomide | Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14. |
| DRUG | Sintilimab placebo and lenalidomide placebo | Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14. |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-08-01
- Completion
- 2021-08-01
- First posted
- 2020-08-19
- Last updated
- 2020-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04518982. Inclusion in this directory is not an endorsement.